PMID- 23828279
OWN - NLM
STAT- MEDLINE
DCOM- 20140501
LR  - 20211021
IS  - 1573-7373 (Electronic)
IS  - 0167-594X (Linking)
VI  - 115
IP  - 1
DP  - 2013 Oct
TI  - Retrospective study of pemetrexed as salvage therapy for central nervous system 
      lymphoma.
PG  - 71-7
LID - 10.1007/s11060-013-1196-1 [doi]
AB  - There is currently no standard therapy for recurrent or chemotherapy-refractory 
      central nervous system lymphoma (CNSL). Pemetrexed has been reported to have 
      activity in patients with primary CNSL (PCNSL). The use of pemetrexed in 
      secondary CNS lymphoma (SCNSL) has not previously been reported. Here we 
      retrospectively review the outcomes and toxicities of standard and modified doses 
      of pemetrexed as salvage therapy in 18 PCNSL and 12 SCNSL patients. The overall 
      response rate for PCNSL patients was 64.7 %, all of whom achieved a complete 
      response (CR). The median progression-free survival (PFS) was 5.8 months. For the 
      SCNSL patients, RR was 58.3 % with 2 CR (16.7 %); the median PFS was 2.5 months. 
      Grade >/=3 adverse events included leukopenia in 5 patients (16.7 %), neutropenia 
      in 1 patient (3.3 %), and fatigue in 3 patients (10.0 %). 3 patients died while 
      on treatment, 2 due to infections and 1 due to pulmonary embolism. Our results 
      indicate that pemetrexed has activity as salvage therapy in recurrent PCNSL, even 
      with modified dosing, but outcomes trend towards less favorable in SCNSL.
FAU - Zhang, Jun-Ping
AU  - Zhang JP
AD  - Department of Neuro-Oncology, Beijing Sanbo Brain Hospital, Capital Medical 
      University, Beijing, China.
FAU - Lee, Eudocia Q
AU  - Lee EQ
FAU - Nayak, Lakshmi
AU  - Nayak L
FAU - Doherty, Lisa
AU  - Doherty L
FAU - Kesari, Santosh
AU  - Kesari S
FAU - Muzikansky, Alona
AU  - Muzikansky A
FAU - Norden, Andrew D
AU  - Norden AD
FAU - Chen, Huichao
AU  - Chen H
FAU - Wen, Patrick Y
AU  - Wen PY
FAU - Drappatz, Jan
AU  - Drappatz J
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
DEP - 20130705
PL  - United States
TA  - J Neurooncol
JT  - Journal of neuro-oncology
JID - 8309335
RN  - 0 (Antimetabolites, Antineoplastic)
RN  - 0 (Glutamates)
RN  - 04Q9AIZ7NO (Pemetrexed)
RN  - 5Z93L87A1R (Guanine)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Antimetabolites, Antineoplastic/*therapeutic use
MH  - Central Nervous System Neoplasms/*drug therapy/pathology
MH  - Female
MH  - Follow-Up Studies
MH  - Glutamates/*therapeutic use
MH  - Guanine/*analogs & derivatives/therapeutic use
MH  - Humans
MH  - Lymphoma, B-Cell/*drug therapy/pathology
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Recurrence, Local/*drug therapy/pathology
MH  - Neoplasm Staging
MH  - Pemetrexed
MH  - Prognosis
MH  - Retrospective Studies
MH  - *Salvage Therapy
MH  - Survival Rate
EDAT- 2013/07/06 06:00
MHDA- 2014/05/03 06:00
CRDT- 2013/07/06 06:00
PHST- 2013/01/18 00:00 [received]
PHST- 2013/06/22 00:00 [accepted]
PHST- 2013/07/06 06:00 [entrez]
PHST- 2013/07/06 06:00 [pubmed]
PHST- 2014/05/03 06:00 [medline]
AID - 10.1007/s11060-013-1196-1 [doi]
PST - ppublish
SO  - J Neurooncol. 2013 Oct;115(1):71-7. doi: 10.1007/s11060-013-1196-1. Epub 2013 Jul 
      5.